Pfizer resolves Promosome patent lawsuit over COVID-19 vaccine

Pfizer (PFE.N), BioNTech (22UAy.DE) and biotech firm Promosome told a federal judge in San Diego, California that they have agreed to end Promosome’s lawsuit accusing the COVID-19 vaccine makers of infringing a patent related to messenger RNA technology.

The companies said in a court filing on Wednesday that Promosome would dismiss its case with prejudice, which means it cannot be refiled, and that Promosome had agreed not to bring future claims over the patent against Pfizer and its partner BioNTech. No financial terms were disclosed.

Representatives for Promosome and Pfizer did not immediately respond to requests for comment on Thursday. A representative for BioNTech’s attorneys declined to comment on the filing.

The agreement comes weeks after Promosome abandoned a related lawsuit against COVID-19 vaccine maker Moderna (MRNA.O).

San Diego and New York-based Promosome was formed to commercialize technology developed by biochemistry researchers at the Scripps Research Institute in La Jolla, California. Promosome sued Pfizer, BioNTech and Moderna in June, accusing the companies of copying its technology for making doses of mRNA small enough to use safely and effectively in the vaccines.

The lawsuits said that Promosome discussed its technology with representatives from Moderna and BioNTech between 2013 and 2016.

Promosome had asked the court for a share of royalties from the shots. Pfizer earned $37.8 billion last year from sales of its COVID-19 vaccine Comirnaty, while Moderna made $18.4 billion from its vaccine Spikevax.

Pfizer and BioNTech denied the allegations and claimed Promosome had withheld information from the U.S. Patent Office when applying for the patent that would have rendered it invalid.

The Promosome lawsuits were among several U.S. patent cases brought by biotech companies over the alleged misuse of their technology in the groundbreaking shots. Moderna filed a patent lawsuit against Pfizer and BioNTech last year that is still ongoing.

PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha 293 cell AAV high-yield platform and the π-Omega plasmid high-yield platform. PackGene's mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.

Related News